The Radionetics platform was built and incubated within Crinetics (CRNX), a leader in GPCR-targeted drug development, prior to our spin out and financing by 5AM Ventures and Frazier Healthcare in October 2021. Our continued collaboration with Crinetics accelerates our early discovery efforts.
Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.